Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
Epithelioid sarcoma (ES) is a rare soft tissue sarcoma with an incidence of 0.05 per 100,000 population in the USA. It is characterized by multiple local recurrences and regional lymph nodes form the commonest site of metastases. The function of Integrase Inhibitor 1 (INI1) protein is lost in more t...
Saved in:
| Main Authors: | Ghazal Tansir, Sameer Rastogi, Shamim Ahmed Shamim, Adarsh Barwad |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2020-0173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epithelioid sarcoma of the hand mimicking Dupuytren's disease: A case report and review of the literature
by: Athanasios Papas, et al.
Published: (2025-06-01) -
Epithelioid sarcoma presenting as recurrent thumb ulcer: A lesson to learn
by: Lakkavalli Krishnappa Rajeev, et al.
Published: (2018-01-01) -
A rare cause of diffuse alveolar hemorrhage in a pediatric patient: thigh localization of INI1-deficient epithelioid sarcoma
by: Xiaolei Tang, et al.
Published: (2025-08-01) -
Prognostic nomogram in patients with epithelioid sarcoma: A SEER‐based study
by: Di Zhang, et al.
Published: (2023-02-01) -
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyResearch in context
by: Junning Cao, et al.
Published: (2025-09-01)